| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | DR5 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6334H9792N1700O2000S42 |
| Molar mass | 143104.43 g·mol−1 |
  (what is this?) (verify) | |
Drozitumab is a human monoclonal antibody in development for the treatment of cancers.[1] It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.[2] Drozitumab was developed by Genentech.
Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.[2]
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab" (PDF). American Medical Association.
- ^ a b "Drozitumab". AdisInsight. Retrieved 31 January 2017.